Biotech Specialty Pharma

Neurotez, Inc.

991 Highway 22, suite 200A
Bridgewater, NJ 08807 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Developing therapeutic manipulation technologies to treat Alzheimer's.

Management Nikolaos Tezapsidis, PhD, President & CEO; Mark A. Smith, PhD, CSO; Jane M. Johnston, PhD, Executive Director of Research and Development; Eugene J. Oliva, MBA, Chief Financial Officer; Michael J. Hoy, M.S., Director of Regulatory Affairs.

Click here for Financial Data
Keywords: biochemistry, molecular, biology, biopharmaceuticals, protein, clinical development, Alzheimer's disease.


Updated: Oct. 03, 2014


Neurotez Inc. is a privately held Delaware corporation formed to launch the clinical development of recombinant human Leptin as a hormone replacement therapy for Alzheimer's disease ("AD"), and as a p......view more

Products / Services

The most advanced product is a recombinant Leptin product for Alzheimer's diseaase.......view more

Market / Customers

Alzheimer's Disease (AD) is the primary cause of cognitive impairment among the elderly (40-50% of 85 yr olds may have AD). There are currently 5.1 million people with AD in the US alone, costing over......view more

Competitors / Substitutes / Alternatives

Currently available AD drugs provide only limited symptomatic relief without addressing the underlying pathobiology of the disease. Drug development programs seeking to address AD are underway at a s...view more


-Pre-IND...view more